- Home
- XOMAP vs SNN Comparison
XOMAP vs SNN Comparison
Compare XOMAP & SNN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- XOMAP
- SNN
- Stock Information
- Founded
- XOMAP N/A
- SNN 1856
- Country
- XOMAP United States
- SNN United Kingdom
- Employees
- XOMAP 13
- SNN N/A
- Industry
- XOMAP Biotechnology: Pharmaceutical Preparations
- SNN Industrial Specialties
- Sector
- XOMAP Health Care
- SNN Health Care
- Exchange
- XOMAP Nasdaq
- SNN Nasdaq
- Market Cap
- XOMAP N/A
- SNN 12.6B
- IPO Year
- XOMAP N/A
- SNN 1999
- Fundamental
- Price
- XOMAP $25.70
- SNN $29.96
- Analyst Decision
- XOMAP
- SNN Hold
- Analyst Count
- XOMAP 0
- SNN 3
- Target Price
- XOMAP N/A
- SNN $27.50
- AVG Volume (30 Days)
- XOMAP N/A
- SNN 900.6K
- Earning Date
- XOMAP N/A
- SNN 07-31-2025
- Dividend Yield
- XOMAP N/A
- SNN 2.40%
- EPS Growth
- XOMAP N/A
- SNN 56.15
- EPS
- XOMAP N/A
- SNN 0.47
- Revenue
- XOMAP N/A
- SNN $5,810,000,000.00
- Revenue This Year
- XOMAP N/A
- SNN $6.87
- Revenue Next Year
- XOMAP N/A
- SNN $5.19
- P/E Ratio
- XOMAP N/A
- SNN $32.14
- Revenue Growth
- XOMAP N/A
- SNN 4.70
- 52 Week Low
- XOMAP N/A
- SNN $23.69
- 52 Week High
- XOMAP N/A
- SNN $31.72
- Technical
- Relative Strength Index (RSI)
- XOMAP 49.53
- SNN 54.99
- Support Level
- XOMAP $25.30
- SNN $29.99
- Resistance Level
- XOMAP $25.95
- SNN $30.77
- Average True Range (ATR)
- XOMAP 0.07
- SNN 0.39
- MACD
- XOMAP -0.01
- SNN 0.01
- Stochastic Oscillator
- XOMAP 60.24
- SNN 65.82
About XOMAP XOMA Corporation 8.625% Series A Cumulative Perpetual Preferred Stock
XOMA Royalty Corp is a biotechnology royalty aggregator playing a role in helping biotech companies achieve their goal of improving human health. XOMA acquires the potential future economics associated with pre-commercial therapeutic candidates that have been licensed to pharmaceuticals or biotechnology companies. XOMA acquires future economic rights, the seller receives non-dilutive, non-recourse funding that can use to advance their internal drug candidate(s) or for general corporate purposes. Geographically, the company operates in Switzerland, United States, Asia Pacific, Europe and Others.
About SNN Smith & Nephew SNATS Inc.
Smith & Nephew designs, manufactures, and markets orthopedic devices, sports medicine and arthroscopic technologies, and wound care solutions. Roughly 41% of the UK-based firm's revenue comes from orthopedic products, and another 30% is sports medicine and ENT. The remaining 29% of revenue is from the advanced wound therapy segment. Over half of Smith & Nephew's total revenue comes from the United States, just over 30% is from other developed markets, and emerging markets account for the remainder.